- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04605549
A Study of CIN-107 in Adults With Primary Aldosteronism
A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients With Primary Aldosteronism
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For patients in Part 1 only :
The treatment duration for patients who complete all 3 dose levels, and who opt not to continue in the extension part of the study, is 12 weeks. For patients who do not complete up-titration, the treatment duration will include at least 4 weeks of dosing with the final dose level. If down-titration of CIN-107 dose is determined at Visit 6 (Week 9), the total treatment duration may be extended to 13 weeks to allow sufficient time for CIN-107 treatment effect at the final dose to be assessed. If the final dose of CIN-107 is reached before week 8 (Visit 5) and no up-titration occurs at Visit 5, the patients will be encouraged to continue CIN-107 treatment till Visit 7 for a total of 12 weeks of treatment. The patients who opt not to continue to Part 2 will not receive any study drug and will return for their safety follow up visit (Visit 8) in 2 weeks.
For patients who opt to continue in the extension part (Part 2) of the study:
Patients will continue to receive their dose of baxdrostat and be instructed to measure BP at least once every week prior to dosing with CIN-107 in the morning, during the extension phase. Safety surveillance will be conducted if clinically indicated. Repeat and unscheduled testing for serum potassium may be measured at the investigator's clinical site or at local laboratory for a faster turn-around time to allow clinical assessment. These patients entering part 2 will skip Visit 8 and their next visit will be Visit 9.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: CinCor Pharma Clinical Trials Contact
- Phone Number: 617-675-8126
- Email: info@cincor.com
Study Locations
-
-
California
-
Greenbrae, California, United States, 94904
- Research Site
-
San Francisco, California, United States, 94110
- Research Site
-
West Hollywood, California, United States, 90048
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Research Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45245
- Research Site
-
Columbus, Ohio, United States, 43210
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75390-9047
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have been diagnosed with PA.
- Are taking mineralocorticoid receptor antagonist (MRA) to control BP; or are newly diagnosed with PA and have not started MRA treatment.
- Are willing and able to cease dosing of MRA for up to 4 weeks in patients taking MRA.
- Are willing to be compliant with the contraception and reproduction restrictions of the study.
- Have increased SBP by ≥ 20 mmHg or have SBP ≥ 160 mmHg after dosing of MRA treatment is ceased for up to 4 weeks duration, or have SBP ≥ 150 mmHg for patients who are newly diagnosed with PA and have not taken an MRA in the past 12 weeks.
Exclusion Criteria:
- At Screening Visit, have a single occurrence of mean seated SBP > 180 mmHg or DBP > 110 mmHg if not taking an MRA; or have a mean seated SBP ≥ 160 mmHg or DBP ≥ 100 mmHg if currently taking an MRA.
- Have a body mass index > 45 kg/m2.
- Have had a previous surgical intervention for an adrenal adenoma or have a planned adrenal carcinoma, adrenalectomy, renal nerve denervation, or adrenal ablative procedure during the course of the study.
- Have a documented estimated glomerular filtration rate < 45 mL/min/1.73 m2.
- Have a planned dialysis, kidney transplantation or any major surgical procedure during the course of the study.
- Have known documented New York Heart Association class III or IV chronic heart failure.
- Have had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before the Screening Visit.
- Have known current severe left ventricular outflow obstruction.
- Have had major cardiac surgery within 6 months before the Screening Visit.
- Have a history of, or currently experiencing, clinically significant arrhythmias.
- Have had a prior solid organ transplant or cell transplant.
- Are positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen.
- Have typical consumption of > 14 alcoholic drinks weekly.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CIN-107 for dosing at 2, 4, or 8 mg (QD)
Patients will be provided with an initial dose of CIN-107 and start once daily (QD) dosing of CIN-107 tablets at 2 mg. At Visit 4, CIN-107 dose may be up-titrated to 4 mg QD if the patient has tolerated dosing of CIN-107 at 2 mg and the blood pressure (BP) records indicate minimal hypotension risk. At Visit 5, CIN-107 dose may be up-titrated to 8 mg QD if the patient has tolerated dosing of CIN-107 at 4 mg. |
One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.
Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.
Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the safety and tolerability of CIN-107
Time Frame: 74 Weeks
|
Outcome measure is overall safety with is a composite of the following individual parameters (unit of measure in brackets):
|
74 Weeks
|
Change in mean seated systolic blood pressure (SBP)
Time Frame: after 12 weeks of treatment
|
Effectiveness measured by change in mean seated SBP after 12 weeks of treatment in patients with PA
|
after 12 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mean diastolic blood pressure (DBP)
Time Frame: after 12 weeks of treatment
|
Comparison of changes in mean SBP after 12 weeks of treatment in patients with PA.
|
after 12 weeks of treatment
|
The percentage of patients achieving a seated blood pressure (BP) response <140/90 mmHg
Time Frame: at Week 12
|
The percent of patients who achieved a seated BP response <140/90 mmHg after CIN107 treatment will be evaluated at each dose level at Week 12.
|
at Week 12
|
The percentage of patients achieving a seated BP response <130/80 mmHg
Time Frame: at Week 12
|
The percent of patients who achieved a seated BP response <130/80 mmHg after CIN107 treatment will be evaluated at each dose level at Week 12.
|
at Week 12
|
The percentage of patients achieving either: - a plasma aldosterone concentration (PAC) < 15 ng/dL and a plasma renin activity (PRA) ≥ 0.5 ng/mL/h; or - an ARR < 15; or - unsuppressed renin activity PRA ≥ 1.0 ng/mL/h
Time Frame: after 12 weeks of treatment
|
after 12 weeks of treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIN-107-122
- D6970C00001 (Other Identifier: AstraZeneca)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Aldosteronism
-
Radboud University Medical CenterCompletedPrimary Aldosteronism | Primary HyperaldosteronismNetherlands
-
Shanghai Jiao Tong University School of MedicineNot yet recruitingPrimary AldosteronismChina
-
University of CalgaryNot yet recruiting
-
Queen Mary University of LondonRecruiting
-
First Affiliated Hospital of Chengdu Medical CollegeNot yet recruitingPrimary AldosteronismChina
-
University College London HospitalsCompletedPrimary Aldosteronism
-
Shanghai Zhongshan HospitalCompleted
-
Qifu LiWest China Hospital; Tongji Hospital; Second Affiliated Hospital, School of Medicine... and other collaboratorsRecruitingPrimary AldosteronismChina
-
Xiao ChenRecruitingPrimary AldosteronismChina
-
Liverpool University Hospitals NHS Foundation TrustRecruiting
Clinical Trials on CIN-107 2 mg dosing
-
AstraZenecaCompletedHypertensionUnited States
-
AstraZenecaCompletedStudy to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal FunctionHypertensionUnited States
-
AstraZenecaCompletedHypertensionUnited States
-
AstraZenecaParexelActive, not recruitingChronic Kidney Diseases | Uncontrolled HypertensionUnited States
-
AstraZenecaCompletedHypertensionUnited States
-
AstraZenecaCompletedHypertensionUnited States
-
AstraZenecaCompleted
-
AstraZenecaNot yet recruitingResistant Hypertension | Uncontrolled HypertensionVietnam, Korea, Republic of, Philippines, China, Hong Kong, Turkey, Japan, India, Russian Federation, Argentina
-
AstraZenecaRecruitingResistant HypertensionSpain, Argentina, United States, Belgium, Czechia, Vietnam, Thailand, Australia, Turkey, Philippines, Greece, Taiwan, United Kingdom, Poland, South Africa, Canada, Germany, Hungary, Malaysia, Bulgaria, Saudi Arabia, Slovakia
-
AstraZenecaRecruitingResistant Hypertension | Uncontrolled HypertensionUnited States, Canada, Italy, South Africa, Korea, Republic of, Australia, Belgium, France, Germany, Poland, Japan, Spain, Vietnam, Argentina, Bulgaria, Turkey, India, Malaysia, Taiwan, Thailand, Austria, Israel, Netherlands, Sweden, United... and more